Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...
The Motley Fool on MSN2d
2 Hot Biopharma Stocks to Buy and Hold for 5 YearsSummit Therapeutics (NASDAQ: SMMT) is a biotech stock that few investors have heard of, but it has the makings of a winner ...
While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Ivonescimab achieves hazard ratio of 0.51, beating pembrolizumab in progression-free survival. Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034.
With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback